New book by Larry Connors Click here Improve your trading - See how
In a release on October 9, the Company noted that net sales increased 4 percent during the first fiscal quarter ended August 31, to $630.1 million from $607.0 million for the first quarter of fiscal year 2009. Excluding the impact of foreign currency, net sales increased 7 percent during the first quarter.
U.S. sales increased 9 percent to $400.2 million during the quarter; Europe sales of $154.8 million decreased 9 percent (increased 3 percent constant currency); and International (primarily Canada, South America, Mexico and the Pacific Rim) sales increased 9 percent to $75.1 million (13 percent constant currency). Excluding dental and the impact of foreign currency, net sales during the first quarter of fiscal 2010 increased 9 percent worldwide, 10 percent in the U.S., 7 percent in Europe, and 10 percent for International.
During the first quarter of fiscal 2010, Biomet reported $113.0 million of special items (pre-tax), including purchase accounting charges of $98.4 million. The purchase accounting charges primarily relate to amortization expense for established intangible assets and depreciation expense as a result of the step-up of property to fair value. The remaining $14.6 million of special items included costs primarily related to the Company's Operational Improvement Program and $5.2 million of stock compensation expense. A reconciliation of reported results to adjusted results is included in this press release, which is also posted on Biomet's website: biomet.com
On a reported basis, operating income for the first quarter totaled $79.1 million compared to operating income of $57.0 million for the first quarter of fiscal year 2009. Excluding special charges and stock compensation expense in both periods, adjusted operating income for the first quarter of fiscal year 2010 increased 12 percent to $192.1 million or 30.5 percent of net sales compared to $171.6 million or 28.3 percent of net sales for the prior year period.
During the first quarter of fiscal 2010, the Company recorded a net loss of $22.8 million, on a reported basis, compared to a net loss of $59.9 million for the first quarter of fiscal 2009. Excluding special charges and stock compensation expense in both periods, adjusted net income totaled $49.2 million during the first quarter compared to $13.8 million for the same period last year.
The Company's interest expense for the first quarter of fiscal year 2010 was $131.5 million compared to $141.9 million for the first quarter of fiscal 2009.
Excluding special charges and stock compensation expense in both periods, adjusted earnings before interest, taxes, depreciation and amortization ("EBITDA") for the first quarter increased 11 percent to $230.3 million, or 36.5 percent of sales, compared to adjusted EBITDA of $207.0 million, or 34.1 percent of sales, for the prior year period.
Free cash flow (operating cash flow minus capital expenditures) was $1.6 million for the first quarter of fiscal 2010. Unlevered free cash flow (cash flow before debt service) totaled $59.8 million. The Company's cash flow in the quarter was negatively impacted by $53 million related to a previously disclosed litigation settlement that is further described in Biomet's 10-Q to be filed later today. Unlevered free cash flow in the first quarter of last year was $21.9 million.
The Company's reported net debt balance at August 31, was $6.010 billion, with cash on hand of $226.4 million. Since the transaction closing date of September 25, 2007, reported net debt has decreased $134.9 million despite a $46.0 million increase in our Euro denominated debt due to the unfavorable impact of foreign currency.
At the end of the first quarter of fiscal 2010, the Company's senior secured leverage ratio was 3.66 times the adjusted last twelve month's ("LTM") EBITDA (including run rate cost savings as defined in the Credit Agreement dated September 25, 2007), compared to 4.7 times at the merger date. As of August 31, the net debt leverage ratio was 6.12 times adjusted LTM EBITDA (including run rate cost savings) compared to 7.7 times at the merger date.
Biomet's President and Chief Executive Officer Jeffrey R. Binder said, "We began fiscal year 2010 with an encouraging quarter. I'm particularly pleased with our global sales growth of 9 percent for orthopedic reconstructive devices, 10 percent growth for knees, 23 percent extremity sales growth and the 17 percent growth rate for spine. Additional product categories that recorded double-digit sales growth during the first quarter include craniomaxillofacial fixation, sports medicine devices and softgoods and bracing products. Further, we experienced another strong quarter of leveraged growth in adjusted EBITDA, for an increase of 11 percent compared to the first quarter of fiscal 2009."
Biomet, Inc. and its subsidiaries design, manufacture and market products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy.
((Comments on this story may be sent to health@closeupmedia.com))
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
